Chemistry:FKW00GA

From HandWiki

FKW00GA, also known as TGW00AA, is a serotonin 5-HT1A receptor partial agonist and serotonin 5-HT2A receptor antagonist which is under development for the treatment of generalized anxiety disorder, social phobia (social anxiety disorder), and sexual dysfunction.[1][2][3][4][5][6] It is taken by mouth.[1]

As of June 2021, FKW00GA is in phase 2 clinical trials for generalized anxiety disorder, social phobia, and sexual dysfunction.[1][2] It has been in phase 2 clinical trials since at least 2018.[6] The drug is under development by Fabre-Kramer Pharmaceuticals.[1][2][3] FKW00GA is a small molecule, but its chemical structure does not yet seem to have been released.[1][2]

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 "FKW 00GA". 15 June 2021. https://adisinsight.springer.com/drugs/800029565. 
  2. ↑ 2.0 2.1 2.2 2.3 "Delving into the Latest Updates on TGW00AA with Synapse". 19 September 2024. https://synapse.patsnap.com/drug/f9e6b8c750da4b3c86d872fb20916e53. 
  3. ↑ 3.0 3.1 "Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders". Pharmacology & Therapeutics 204. December 2019. doi:10.1016/j.pharmthera.2019.107402. PMID 31470029. 
  4. ↑ "Future Targets for Female Sexual Dysfunction". The Journal of Sexual Medicine 13 (8): 1147–1165. August 2016. doi:10.1016/j.jsxm.2016.05.016. PMID 27436073. 
  5. ↑ "Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions". Expert Review of Neurotherapeutics 23 (6): 535–548. June 2023. doi:10.1080/14737175.2023.2211767. PMID 37183813. 
  6. ↑ 6.0 6.1 "5-HT1A receptor ligands and their therapeutic applications: review of new patents". Expert Opinion on Therapeutic Patents 28 (9): 679–689. September 2018. doi:10.1080/13543776.2018.1514011. PMID 30124346. 




Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:FKW00GA&oldid=4032141"